Treatment Information

Back

Kidney (Renal) Cancer treatment details. Immunotherapy.

Edward Hines Jr VA Hospital, Illinois, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Illinois
Treatments:ImmunotherapyHospital:Edward Hines Jr VA Hospital
Drugs:Journal:Link
Date:Apr 2002

Description:

Patients: This Phase II study involved 44 patients with metastatic renal cell carcinoma; 32 men and 12 women. The median age was 56 years. Prior treatments had included nephrectomy (19 patients) and radiation therapy (5 patients).

Treatment: The treatment consisted of immunotherapy – interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b).

Toxicity: Grade 3-4 toxicities included hematologic, hyponatremia, hepatic, metabolic, gastrointestinal, nausea, diarrhea, stomatitis, renal, hypotension, neurologic, and dyspnea.

Results: The median survival was 13 months.

Support: The study was supported by grants from Chiron Therapeutics and Schering Plough Corporation. Chiron holds a patent on IL-2 and Schering Plough markets IFN alpha-2b.

Correspondence: Dr. J.I. Clark




Back